Induction of apoptosis in myeloid leukaemic cells by ribozymes targeted against AML1/MTG8 by Matsushita, H et al.
The t(8;21)(q22;q22) translocation is one of the specific chromo-
some translocations which exists in 7–17% of the cases with acute
myeloid leukaemia (AML) and is usually classified as AML M2
according to the French–American–British (FAB) classification
criteria (Koeffler, 1987; Schiffer et al, 1989; Tashiro et al, 1992).
This translocation results in the formation of the AML1/MTG8
chimeric fusion gene, which has a 5¢ portion of the AML1 gene on
chromosome 21 which is fused almost to the entire MTG8 gene,
also called ETO gene, on chromosome 8 (Erickson et al, 1992;
Miyoshi et al, 1993).
The AML1 is a member of transcriptional factors which contain
a region of homology to the Drosophila pair-rule gene, runt
(Miyoshi et al, 1993). The runt homology domain is responsible
for heterodimerization with core binding factor b (CBFb) (Lenny
et al, 1995) and specific binding to the sequence TGT/cGGT
which is the enhancer core motif (Meyers et al, 1993). Several
target genes for AML1 have been identified such as neutrophil
elastase, myeloperoxidase, GM-CSF, IL-3, M-CSF receptor and
TCRb enhancer (Cameron et al, 1994; Nuchprayoon et al, 1994;
Zhang et al, 1994, 1996; Frank et al, 1995; Meyers et al, 1995;
Takahashi et al, 1995). AML1 has been found to transactivate the
regulatory segments of each of these genes. Three representative
forms of proteins, AML1a, AML1b and AML1c, are produced
from the AML1 gene by alternative splicing (Miyoshi et al, 1995).
AML1a and AML1b are thought to regulate haematopoietic
myeloid cell differentiation and transcriptional activation antago-
nistically (Tanaka et al, 1995). The function of the AML1 protein
is regulated by extracellular signal-regulated kinase (ERK), a
member of the mitogen-activated protein kinases through phos-
phorylation (Tanaka et al, 1996). An in vivo study revealed that
mice lacking AML1 are embryonically lethal without myeloid or
erythroid progenitors originating from definitive haematopoiesis
(Okuda et al, 1996; Wang et al, 1996). These data indicate that
AML1 is one of the essential transcriptional factors for the defini-
tive haematopoiesis of all types of cell lineage.
AML1/MTG8 chimeric protein shares structural features with
these genes and also demonstrates the runt homology domain
(Miyoshi et al, 1993). AML1/MTG8 is thought to interfere with
AML1b-dependent transcriptional activation as a dominant nega-
tive protein (Meyers et al, 1993, 1995). The antisense oligo-
nucleotide targeted against AML1/MTG8 fusion transcript
inhibited the growth of the AML cell lines with t(8;21)(q22;q22)
(Sakakura et al, 1994). Therefore, AML1/MTG8 chimeric fusion
protein is considered to play an important role in the leukaemoge-
nesis of acute myeloid leukaemia with t(8;21)(q22;q22).
Hammerhead ribozymes are one of the useful tools for the
specific inhibition of gene expression (Haseloff and Gerlach, 1988).
They are oligoribonucleotides with sequence-specific cleavage
activity of target RNA and can be designed to cleave any triplet of
NUX (N = any nucleotide, X = A, C or U) (Koizumi et al, 1988).
One molecule of ribozyme can cleave a plural number of target
RNAs by repeating the catalytic cycle. Therefore ribozymes are
thought to be more effective than antisense oligonucleotides to
suppress the expression of the target genes (Homann et al, 1993).
We have designed two hammerhead ribozymes against
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Summary The translocation (8;21)(q22;q22) is a karyotypic abnormality detected in acute myeloid leukaemia (AML) M2 and results in the
formation of the chimeric fusion gene AML1/MTG8. We previously reported that two hammerhead ribozymes against AML1/MTG8 cleave this
fusion transcript and also inhibit the proliferation of myeloid leukaemia cell line Kasumi-1 which possesses t(8;21)(q22;q22). In this study, we
investigated the mechanisms of inhibition of proliferation in myeloid leukaemic cells with t(8;21)(q22;q22) by ribozymes. These ribozymes
specifically inhibited the growth of Kasumi-1 cells, but did not affect the leukaemic cells without t(8;21)(q22;q22). We observed the
morphological changes including chromatin condensation, fragmentation and the formation of apoptotic bodies in Kasumi-1 cells incubated
with ribozymes for 7 days. In addition, DNA ladder formation was also detected after incubation with ribozymes which suggested the induction
of apoptosis in Kasumi-1 cells by the AML1/MTG8 ribozymes. However, the ribozymes did not induce the expression of CD11b and CD14
antigens in Kasumi-1 cells. The above data suggest that these ribozymes therefore inhibit the growth of myeloid leukaemic cells with
t(8;21)(q22;q22) by the induction of apoptosis, but not differentiation. We conclude therefore that the ribozymes targeted against AML1/MTG8
may have therapeutic potential for patients with AML carrying t(8;21)(q22;q22) while, in addition, the product of the chimeric gene is
responsible for the pathogenesis of myeloid leukaemia.
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Correspondence to: M KizakiAML1/MTG8 which specifically cleaved the AML1/MTG8
substrate in a cell-free system and also inhibited the growth of
Kasumi-1 cells, an AML cell line with t(8;21)(q22;q22)
(Matsushita et al, 1995). The purpose of this report is to disclose
the mechanism of growth inhibition of AML cells with
t(8;21)(q22;q22) by these ribozymes. We herein demonstrate for
the first time that ribozymes can inhibit the proliferation of
myeloid leukaemic cells by the induction of apoptosis, but not
differentiation.
MATERIALS AND METHODS
Cells and chemicals
The myeloid leukaemic cell line Kasumi-1 established from a
patient with AML M2 carrying t(8;21)(q22;q22) was a generous
gift of Dr N Kamada (Hiroshima University, Horoshima, Japan)
(Asou et al, 1991). The other human myeloid leukaemic cell lines
used in this study were HL-60, KG-1, NB4 (a gift from Dr M
Lanotte, Hôpital St. Louis, Paris, France) (Lanotte et al, 1991) and
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Figure 1 Structures of two hammerhead ribozymes Rz1 and Rz2 targeted against AML1/MTG8, and unrelated scramble ribozyme (ScRz). These
hammerhead ribozymes were designed based on the model of Haseloff and Gerlach (1988). Rz1 cleaves the CUC sequence located three bases upstream
from the break point and Rz2 cleaves the AUC sequence located three bases downstream from the breakpoint. These two hammerhead ribozymes specifically
cleaved the AML1/MTG8 substrate in a cell-free system, as expected (Matsushita et al, 1995). ScRz has random nucleotides in 3¢- and 5¢-complementary arms,
and thus it was not able to cleave the AML1/MTG8 substrate. ‘N’ means any nucleotidesUF-1 (established in our laboratory) (Kizaki et al, 1996) cells. The
cells were all maintained in RPMI 1640 medium (GIBCO-BRL,
Gaithersburg, MD) with 10% fetal bovine serum (FBS)
(Cytosystems, New South Wales, Australia), 100 U ml–1 penicillin
and 100 mg ml–1 streptomycin in a humidified atmosphere with
5% CO2. All-trans-retinoic acid (RA) was purchased from the
Sigma Chemical Co. (St. Louis, MO), and dissolved in 100%
ethanol to stock concentration of 1 mM, stored at –20°C and
protected from light.
Production of ribozyme
The designs of ribozymes targeted against AML1/MTG8, Rz1 and
Rz2, are illustrated in Figure 1. We also designed scramble
ribozyme (ScRz) which has random ribonucleotides in 3¢- and
5¢-complementary arms (Figure 1). Rz1, Rz2 and ScRz were
produced by in vitro transcription as described previously
(Matsushita et al, 1995). Briefly, the template cDNA for Rz1 is 5¢-
GAG AAC CTT TCG ACC TCA CGG TCT CAT CAG GAA ATC
GTA CCC TAT AGT GAG TCG TAT TAC ATG-3¢, that for Rz2 is
5¢-CCT CGA AAT TTC GTC CTC ACG GAC TCA TCA GGT
ACT GAG CCC TAT AGT GAG TCG TAT TAC ATG-3¢ and that
for ScRz is 5¢-NNN NNN NNT TTC GTC CTC ACG GAC TCA
TCA GNN NNN NNN CCC TAT AGT GAG TCG TAT TAC ATG-
3¢. They were mixed with the other oligodeoxynucleotide, 5¢-CAT
GTA ATA CGA CTC ACT ATA GGG-3¢, to form a hemiduplex,
and then they were incubated at 37°C for 4 h in a 200-ml volume
containing 6 mM MgCl2, 2 mM each of ATP, GTP, CTP and UTP
(Boehringer Mannheim, Indianapolis, IN), 240 U of rRNasin
(Promega, Madison, WI, USA), 1000 U of T7 RNA polymerase
and buffer for T7 RNA polymerase (New England Biolabs,
Beverly, MI, USA). After incubation with 20 U of RQ1 RNase-free
DNase (Promega) at 37°C for 15 min, phenol–chloroform extrac-
tion and ethanol precipitation was performed. The produced
ribozyme was resuspended in DEPC-treated water and then the
concentration was checked with a spectrophotometer.
Ribozyme transfection into various leukaemic cells
with lipofection
Ribozymes were transfected into various myeloid leukaemia cell
lines with DOTAP (Boehringer Mannheim) for 5 days as described
(Matsushita et al, 1995).
Assays for cellular proliferation
The cells were incubated for 5 days with and without ribozymes
(Rz1, Rz2 and ScRz) in a 96-well plate (Flow Laboratories, Irvine,
CA, USA). Twenty microlitres of MTT (5 mg ml–1) were added to
each well. The reaction was stopped after 4 h of incubation by adding
100 ml of 0.04 N HCl in propranol and then the OD570 was measured.
Detection of target RNA cleavage by ribozymes
This quantification of cleavage activity by ribozymes was based on
the modified method by Leopold et al (1995). Briefly, UF-1 cells
(1 ´ 106) which carry t(15;17) were added to various amounts
(0–5  ´ 103) of Kasumi-1 cells carrying t(8;21). Two hundred micro-
grams of ribozymes with 37.5 mg of DOTAP and 2000 U of
rRNasin in 5 ml of Opti-MEM I Reduced Serum Medium (GIBCO-
BRL) were added and incubated at 37°C for 12 h, and then 5 ml of
RPMI 1640 medium with 20% FBS was added and incubated at
37°C for a further 12 h. The cells were then harvested, and the total
RNA was isolated with Isogen (Nippongene, Toyama, Japan), and
1 mg of RNA was then applied to the reverse transcription-poly-
merase chain reaction (RT-PCR). RT was performed with
Superscript II (GIBCO-BRL) and random primers; pd(N)6 (Takara
Shuzo, Shiga, Japan) at 37°C for 60 min. PCR was performed with
Taq Polymerase (Perkin-Elmer Cetus, Norwalk, CT, USA). The
thermal condition of PCR was as follows: precycle at 94°C for 5
min followed by 40 cycles at 94°C for 1 min, 60°C for 1 min and
72°C for 1 min. The primers for the amplification of AML1/MTG8
were 4S [5¢-GAC CAT CAC TGT CTT CAC AA-3¢, residue 2022
to 2041 in AML1 (Miyoshi et al, 1993)] and 5R [5¢-GTC TTC ACA
TCC ACA GGT GA-3¢, residue 2143 to 2162 in MTG8 (Miyoshi et
al, 1993)] which was used in our previous study (Muto et al, 1996).
The  b-actin gene was amplified with Human b-Actin Control
Amplimer Set (Clontech, Palo Alto, CA, USA) as an internal
control. The PCR products were electrophoresed in 3% agarose gel
and subsequent Southern blot analysis was performed with the ECL
3¢-oligolabelling and detection systems (Amersham, UK). The
probe sequence for the AML1/MTG8 junction site was 8P (Muto et
al, 1996) [5¢-CGA GAA CCT CGA AAT CGT ACT GAG A-3¢,
residue 2098 in AML1 to 2122 in MTG8 (Miyoshi et al, 1993)]. The
density of the signals on the autoradiographs were analysed with
Digital Densitorol DM-303 (Advantec Toyo, Tokyo, Japan).
Detection of DNA ladder formation in Kasumi-1 cells by
ribozymes
After incubation with ribozymes for 7 days, Kasumi-1 cells were
washed with PBS twice and then DNA was extracted by incu-
bating with 100 ml of buffer which includes 10 mM Tris-HCl
(pH 7.4), 0.5 M EDTA (pH 8.0) and 0.5% Triton X-100 at 4°C for
10 min. After centrifugation, the supernatant was transferred into a
new tube and incubated at 37°C for 1 h with 40 mg of RNase A
(Sigma), and for a further hour with 40 mg of Proteinase K
(Sigma). Ethanol precipitation was performed and resuspended
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Figure 2 Inhibitory effect on myeloid leukaemia cell lines by Rz1 and Rz2.
Cells (2 ´ 104) were incubated with 4 mg of ribozymes (Rz1 or Rz2), 0.75 mg
of DOTAP and 40 U of rRNasin in 100 ml of Opti-MEM I Reduced Serum
medium. After 12 h, 100 ml of RPMI 1640 medium containing 20% FBS were
added to the culture medium. Then 100 ml of supernatant was replaced by an
equal amount of RPMI 1640 medium containing 10% FBS, 4 mg of
ribozymes, 0.375 mg of DOTAP and 20 U of rRNasin each day. Cell growth
was evaluated with an MTT assay after a 5-day incubation. The results are
expressed as the percentage of OD570 nm in various cell lines treated with
ribozymes compared with control cultured with only DOTAP in each cell linewith TE buffer. Purified DNA was labelled with 32P-dCTP and
labelled DNA was then electrophoresed in 1.8% agarose gel (Rösl,
1992). The gel was then dried on 3MM Whatman paper and there-
after autoradiography was performed.
Assays for cellular differentiation by ribozymes
After incubation for 5 days with ribozymes, the cells were incu-
bated for 30min with human AB serum, and then were stained
with PE-conjugated mouse anti-human CD11b antibodies and
FITC-conjugated mouse anti-human CD14 antibodies (Becton
Dickinson, San Jose, CA). Control studies were performed with
a nonbinding control mouse IgG isotype antibody (Becton
Dickinson). A flow cytometric analysis was performed with Ortho
Cytoron Absolute (Ortho Diagnostic systems, Tokyo, Japan).
RESULTS
Cell-specific inhibition by ribozymes against
AML1/MTG8
To confirm the cell-specific inhibition by ribozymes against
AML1/MTG8  , we transfected these ribozymes into various
myeloid leukaemia cell lines, including Kasumi-1, HL-60, KG-1,
U937, NB4 and UF-1 cells. Incubation with myeloid leukaemic
cells and ribozymes for 5 days and then cellular proliferation was
evaluated by an MTT assay. Both ribozymes only inhibited the
proliferation of Kasumi-1 cells, but not the other myeloid
leukaemia cell lines. Rz2 was slightly more potent than Rz1 in
decreasing the absorbance of the MTT assay (Figure 2). These
results suggest that Rz1 and Rz2 specifically inhibit the growth of
myeloid leukaemia cells carrying t(8;21)(q22;q22).
Cleavage activity of ribozymes in cells
To address the specific cleavage activity of ribozymes against
AML1/MTG8  in vitro, we next transfected Rz2 into Kasumi-1 cells
diluted with UF-1 cells. UF-1 cells were used for dilution because
they do not have t(8;21)(q22;q22), and were not inhibited by Rz1
and Rz2 while they also demonstrated a long doubling time (72h)
(Leopold et al, 1995) (Figure 2 and data not shown). Rz2
decreased the detectable level of AML1/MTG8  mRNA at all corre-
sponding lanes (Figure 3). The signal intensity was decreased to
41.1% by Rz2 in the presence of 5 ´103 Kasumi-1 cells (Figure 3).
These results suggest that the growth inhibition of myeloid
leukaemia cells with t(8;21)(q22;q22) by ribozymes are thus
thought to be due to the reduction of AML1/MTG8  mRNA.
Detection of apoptosis in Kasumi-1 cells by ribozymes
After 7 days of culture in Rz1-, Rz2- and ScRz-transduced Kasumi-
1, HL-60, NB4 and U937 cells by lipofection, morphological
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Figure 3Decreased expression of AML1/MTG8 mRNA in ribozyme-treated
Kasumi-1 cells. Kasumi-1 cells (0–5 ´103) were mixed with UF-1 cells
(1 ´106), a myeloid leukaemia cell line without t(8;21), in 5ml of Opti-MEM I
Reduced Serum medium. The cells were transfected with 200mg of
ribozymes, 37.5mg of DOTAP and 2000U of rRNasin. After 12h incubation
at 37°C, 5ml of RPMI 1640 medium with 20% FBS was added to the
medium and incubated for more 12h. Thereafter, 1mg of RNA was applied to
RT-PCR performed with Superscript II and random primers, and a
subsequent Southern blot analysis were performed. Expression of
AML1/MTG8transcript relative to b-actin in each corresponding lane was
determined by densitometer
Control ScRz Rz 1
Kasumi-1
HL-60
NB4
U937
Figure 4Morphological changes of ribozyme-treated Kasumi-1, HL-60,
NB4 and U937 cells. Cells were incubated with ribozymes (Rz1 and Rz2)
and scramble ribozyme (ScRz) as a control for 7 days. Giemsa staining was
performed after cytospin (original magnification, ´1000)
Figure 5 Effects of ribozymes against AML1/MTG8 chimeric transcript and
ScRz on apoptosis in Kasumi-1 cells. Kasumi-1 cells were treated with
ribozymes (Rz1 and Rz2), ScRz or DOTAP alone (control) up to 7 days. The
percentage of cells exhibiting morphological characteristics of apoptosis was
determined on cytospin slides stained with Giemsa
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ScRzchanges of apoptosis in only Kasumi-1 cells occurred with chro-
matin condensation, fragmentation, and the formation of apoptotic
bodies (Figure 4). However, neither Rz1 or Rz2 induced apoptosis
of myeloid leukaemic cells without t(8;21). In addition, ScRz, an
unrelated ribozyme, did not respond to Kasumi-1 cells (Figure 4).
The time course of the appearance of apoptotic cells during
Kasumi-1 culture for 7 days was determined (Figure 5). In Rz1-
and Rz2-treated Kasumi-1 cells, the percentage of apoptotic cells
began to increase after day 3, and became maximal at day 5 (35%
with Rz1 and 32% with Rz2). In contrast, apoptosis was not
induced by the treatment of ScRz and DOTAP alone (control) in
Kasumi-1 cells over a 7-day period (Figure 5). Apoptosis was also
confirmed by DNA electrophoresis which showed a pattern of
DNA fragments that results from the activation of endogeneous
endonuclease (Figure 6). Taken together, these results indicate that
the ribozymes against AML1/MTG8 chimeric transcript specifi-
cally inhibited the proliferation of Kasumi-1 cells through the
apoptotic pathway.
Investigation of differentiation in Kasumi-1 cells by
ribozymes
Induction of differention of Kasumi-1 cells into mature granulo-
cytes or monocytes by Rz1 and Rz2 was assumed by the expres-
sion of CD11b and CD14 antigens. NB4 cells were treated with
all-trans RA (10–7 M) for 4 days and a cell surface marker analysis
was performed as a positive control. All-trans RA induced differ-
entiation of NB4 cells to mature granulocytes and increased the
expression of CD11b antigen by six-fold as compared with the
control cells (Figure 7 and data not shown). However, all-trans RA
as well as Rz1 and Rz2 did not individually alter the expression of
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Figure 6 Detection of DNA ladder formation in Kasumi-1 cells by
ribozymes. Kasumi-1 cells were incubated with ribozymes for 5 days, after
harvesting the cells. DNA was extracted and labelled with 32P-dCTP.
Thereafter, it was electrophoresed in 1.8% agarose gel and then
autoradiography was performed. DNA ladder formation was detected in the
Kasumi-1 cells treated with ribozymes. DNA from the Kasumi-1 cells
incubated without ribozymes was used as a negative control. DNA from
HL-60 cells treated with all-trans retinoic acid was used as a positive control
Figure 7 Expression of CD11b and CD14 antigens by a FACS analysis.
NB4 and Kasumi-1 cells were treated with all-trans RA (10–7 M) for 4 days.
Kasumi-1 cells were also incubated with liposome alone and ribozymes
against AML1/MTG8 (Rz1 and Rz2) for 5 days. The cells were incubated for
30 min with human AB serum to block Fc receptors and then were stained
with direct immunofluorescence using FITC-conjugated mouse antihuman
CD14 and PE-conjugated mouse antihuman CD11b antibodies. Control
studies were performed with non-binding control mouse IgG1 and IgG2a
isotype antibodies
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All-trans RAboth antigens in Kasumi-1 cells by a flow cytometric analysis. In
addition, no morphological changes accompanied with differentia-
tion were observed in the Rz1-treated Kasumi-1 cells (Figure 4).
DISCUSSION
AML1/MTG8 is thought to play a key role in leukaemogenesis
because the growth of leukaemic cells with t(8;21)(q22;q22) was
inhibited by antisense oligonucleotides or ribozymes against
AML1/MTG8 fusion transcript (Sakakura et al, 1994 ;Matsushita et
al, 1995; Kozu et al, 1996). The molecular mechanism of leukae-
mogenesis by AML1/MTG8 has been studied, and AML1/MTG8
has been shown to block AML1b transcription as the dominant
negative protein which is mediated by the runt homology domain
(Meyers et al, 1993, 1995). More recently, it has reported that
AML1 is essential for definitive haematopoiesis of all lineages by
using AML1 knockout mice (Okuda et al, 1995; Wang et al, 1996)
and AML1/MTG8 knock-in analyses (Yergeau et al, 1997; Okuda et
al, 1998). On the other hand, few studies about the biological effect
of AML1/MTG8 have been reported which suggest that Kasumi-1
cells were induced to differentiate to monocytic lineage by anti-
sense oligonucleotide complementary to the AML1/MTG8 tran-
script, however, only 12% of the cells treated with 10 mM
antisense oligonucleotide were positive for NSE staining (Sakakura
et al, 1994).
We constructed two hammerhead ribozymes targeted against
AML1/MTG8, and proved that these ribozymes cleaved the target
substrate specifically in a cell-free system and also inhibited the
growth of leukaemic cells with t(8;21)(q22;q22) (Matsushita et al,
1995). Another group has also reported similar results (Kozu et al,
1996), however, the mechanisms of the ribozymes against
AML1/MTG8 on the growth inhibition of myeloid leukaemic cells
have yet to be elucidated. The ribozyme-induced apoptotic cells were
identified based on morphology. The percentage of apoptotic cells
was increased in a time-dependent manner by ribozymes targeted
against AML1/MTG8. In contrast, apoptosis was not induced by the
treatment of unrelated ribozyme. Therefore, the ribozyme-induced
growth inhibition of Kasumi-1 cells was associated with the induc-
tion of apoptosis. We could also detect DNA ladder formation in
ribozyme-treated Kasumi-1 cells. These findings suggest that the
decrease in the expression of AML1/MTG8 by ribozymes may thus
induce leukaemic cells to apoptosis, and this is the first report which
suggests that blocking the expression of AML1/MTG8 by ribozymes
induces apoptosis of leukaemic cells. A previous report showed that
AML1/MTG8 fusion protein activates the transcription of Bcl-2
(Klampfer et al, 1996). We therefore examined the expression of
Bcl-2, Bcl-Xs/L and Bax in ribozyme-treated Kasumi-1 cells by a
Western blot analysis, however, the expression of these proteins was
equal to those in the nontreated cells (data not shown). Further
studies are thus needed to clarify the molecular mechanisms of
apoptosis in ribozyme-treated leukaemic cells.
A previous study reported that the antisense oligonucleotide
complementary to AML1/MTG8 inhibited the growth and induced
differentiation of the cell lines derived from AML containing
t(8;21) (Sakakura et al, 1994). However, we could not observe any
apparent morphological differentiation changes in the ribozyme-
treated Kasumi-1 cells, or any apparent increase in the granulo-
cytic lineage marker CD11b and monocytic lineage marker CD14
in these cells by a flow cytometric analysis. These data suggest
that the induction of differentiation did not occur in the ribozyme-
mediated growth inhibition of Kasumi-1 cells.
The transduction efficiency was evaluated by methods based on
those of Leopold et al (1995) and the ribozyme decreased the level
of target RNA with liposome by one-log in their study. The reduc-
tion of target RNA in our case was thus the same level as that
reported in their study (Figure 3). It is possible that a more effec-
tive induction of apoptosis might also occur by improving the
transduction method.
In summary, we observed both specific growth inhibition and
the induction of apoptosis by inhibiting the expression of chimeric
RNA by ribozymes in Kasumi-1 cells. Therefore, chimeric RNA
may be useful as therapeutic targets in patients with AML.
Ribozymes are thus expected to be potentially useful as specific
gene modifiers for various malignancies including leukaemia
(Lange et al, 1993; Shore et al, 1993; Snyder et al, 1993; Pace et al,
1994; Pachuk et al, 1994). We thus conclude that ribozymes may
be useful as a new therapy based on the molecular pathogenesis in
the treatment of AML with t(8;21).
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